The 19th term Annual #ShareholdersMeeting was held, and more shareholders attended than last year. We have adopted a hybrid remote attendance-type virtual shareholders meeting. This type of meeting allows shareholders to exercise their voting rights and ask questions online. This type is an #AdvancedInitiative adopted by few companies out of more than 2,000 listed companies in Tokyo Stock Exchange that hold their annual shareholders meeting in June 2024. The "Notice of Resolution,” "Results of Exercise of Voting Rights,” "Questions and Answers from Shareholders” and “Annual Shareholders Meeting Script” have been published on our corporate website. Click here to learn more: https://lnkd.in/gEFeZnCt #HybridRemoteAttendanceType #VirtualShareholdersMeeting
概要
アステラス製薬は、最先端の「価値」駆使型ライフサイエンス・イノベーターを目指しています。革新的なサイエンスを患者さんにとって最良のアウトカムにつなげるために、医療変革の最前線で活動しています。世界約70か国で14,000人以上の従業員が勤務し、科学の進歩を追求し、アンメットメディカルニーズに応えるよう、事業活動に取り組んでいます。 このページ内でのコミュニケーションについては「アステラスグローバルLinkedInコミュニティガイドライン」をご覧ください。https://www.astellas.com/jp/global-linkedin-community-guidelines
- ウェブサイト
-
http://www.astellas.com/
アステラス製薬の外部リンク
- 業種
- 医薬品製造業
- 会社規模
- 社員 10,001名以上
- 本社
- Chuo-Ku、Tokyo
- 種類
- 上場企業
- 専門分野
- Pharmaceuticals、医薬品
場所
-
2-5-1, Nihonbashi-Honcho
Chuo-Ku、Tokyo、103-8411、JP
アステラス製薬の社員
-
Chad Stewart
Innovating Healthcare Strategy & Culture to improve peoples' lives and well-being
-
Jason Hill, Ph.D.
Precision Medicine
-
Achim v. Montigny
CONNECTING TALENTS WITH TECHNOLOGY INNOVATORS | EXECUTIVE SEARCH | INTERIM RECRUITING | BUSINESS DEVELOPMENT
-
Roderick P.
Director, EMEA Order to Cash Process Owner, Global Business Services
アップデート
-
We are thrilled to contribute to the second edition of the Good Patient Partnership Guide, inspiring meaningful conversations and progress towards patient-centric practices. At Astellas, patient centricity is at the core of our global company culture. We take pride in the transformation we have achieved since establishing the Patient Centricity division five years ago, and eagerly anticipate the continued evolution of the industry and regulatory bodies to prioritize patients and caregivers in decision-making. Join us in creating a truly patient-centric future. Read the latest guide here: https://lnkd.in/eAEqVRMT
-
-
Remarkable advances in oncology innovation are poised to change the landscape of cancer care as we know it – but complex challenges remain. Bringing together innovative science with cutting-edge technologies in new and exciting ways will enable us to reimagine traditional drug development approaches so that we can deliver better treatments to patients, faster. Senior Vice President and Head of Oncology Development, Ahsan Arozullah, recently joined a roundtable discussion at #ASCO24 hosted by SCRIP and ICON plc, sharing his perspectives on how to harness the potential of new technologies. Read more: https://bit.ly/3LtSavM. #ChangingTomorrow #ScienceFirstForPatients
-
Astellas and Graduate School of Medicine / Faculty of Medicine, Osaka University ("Osaka University") today announced that Astellas Institute for Regenerative Medicine (a wholly owned subsidiary of Astellas), Universal Cells (a wholly owned subsidiary of Astellas) and Osaka University have entered into a research collaboration to develop innovative pluripotent stem cell-derived cartilage organoid cell therapy for the treatment of intervertebral disc degenerative disease. Click on the link below or on the image to learn more: https://lnkd.in/ggyipRCG #BlindnessAndBeyond #ResearchCollaboration #ResearchAgreement
-
-
It was an honor to be with the eye care community at the American Society of Retina Specialists (ASRS) 2024 meeting and connect with those who share our passion for helping patients impacted by vision loss. Thank you to everyone who attended and made ASRS a success! #Ophthalmology #ASRS2024 #EyeHealth
-
-
Headed to the American Society of Retina Specialists (ASRS) meeting? Join us at booth 205 to learn more about Astellas’ commitment to advancing innovation in ophthalmology. Our team can’t wait to get to Stockholm and engage with experts who share our mission. #ASRS2024 #EyeHealth #Ophthalmology
このコンテンツはここではご利用いただけません
このコンテンツなどにLinkedInアプリでアクセス
-
El pasado mes de junio hemos estado de celebración: se cumplieron 5 años desde la creación de nuestra división de Patient Centricity, como una función independiente, consolidando nuestro compromiso por ser una compañía verdaderamente centrada en el paciente. Para Astellas, los pacientes están en el centro de todo lo que hacemos, es decir, son nuestra razón de ser. Tanto es así, que nuestro lema es justo ese: PATIENTS ARE WHY. Pero este compromiso no son solo palabras, sino que se traduce a hechos. Trabajamos incansablemente junto a entidades como Ader Asociación , AEAL, Asociación Española de Afectados por Linfoma, Mieloma y Leucemia, la Alianza General de Pacientes (AGP), Federación Nacional de Asociaciones ALCER, ANCAP. Asociación de Cáncer de Próstata,ASIA - Asociación para la Incontinencia anal, Federación ASEM -Federación Española de Enfermedades Neuromusculares, EUPATI España, Foro Español de Pacientes, FNETH, GEPAC - GRUPO ESPAÑOL DE PACIENTES CON CANCER, Asociación Mácula Retina, Pequeños Superhéroes Asociación, la Asociación Española de Enfermos de Pompe y Plataforma de Organizaciones de Pacientes. A todos vosotros, muchas gracias por dejarnos ser parte de vuestro día a día. Y, aunque nuestro Mes del Paciente haya finalizado, nuestra acción continúa. Por eso os dejamos con este vídeo en el que hemos preguntado a las asociaciones con las que trabajamos qué les inspira en su trabajo diario. #AstellasEspaña #PatientCentricity #PATIENTSAREWHY Gaceta Médica
-
We are thrilled to announce the continued collaboration between Astellas and Patient Advocacy Leaders and Drug Development Industry Network (PALADIN), as well as the launch of the highly anticipated PALADIN Playbook and Resource Repository. This collaboration represents an important milestone in our efforts to advance patient advocacy group (PAG) and industry collaborations, with the ultimate goal of increasing access to life-saving treatments. PALADIN Consortium, in which Astellas is an active participant, plays a pivotal role in establishing more effective relationships between PAGs and biopharmaceutical companies. By developing consensus-based guidelines, training, resources, and competencies, PALADIN aims to optimize collaborations and transform the pace of new medical therapies' development. We are excited about the potential of this collaboration and the impact it will have on relevant stakeholders and the community. Together, we can create meaningful change and drive progress in the industry. Stay tuned for further updates and announcements as we continue this exciting journey with PALADIN. For more information, including PALADIN Playbook and Resource Repository, visit https://lnkd.in/gPk4H8M7. #PatientAdvocacy
PALADIN Consortium - Home
https://sites.tufts.edu/paladinconsortium
-
Over the past few decades, we’ve seen the gradual improvement in cancer outcomes for patients around the world. As part of this, the emergence of innovation in combination therapies is offering patients with cancer a clinically effective treatment option. However, there are significant challenges that payers, healthcare systems and partners must contend with if we want to ensure timely access to the best care for people affected by cancer. Today marks the launch of a new report ‘A framework for value-aligned pricing of combination therapies,’ commissioned by the Office of Health Economics (OHE) and Astellas. The report calls on the wider healthcare community to turn its attention to a bespoke access model for when a medicine is used in combination. We hope that this will help move us one step closer to a system where patients have access to combination therapies in a fair, timely, and sustainable way. It’s vital that we work together with payers, policymakers and industry leaders. We must act now to ensure we have a reimbursement framework that can enable access to these innovative therapies and move with the times as innovation shifts from singular to multiple treatments. Read the full report at: https://lnkd.in/gFJ-yrdD #Healthcare #Innovation #CombinationTherapy #PatientAccess
-
-
We are thrilled to announce that Astellas has been named a winner of the CSO Awards. This esteemed recognition is a testament to the collective efforts of the Information Security team in implementing security projects and initiatives that have demonstrated outstanding business value and thought leadership. The CSO Awards recognize exceptional efforts in addressing challenges from an expanding threat landscape. These projects include new threat detection methods, advancements in cyber analytics, and strategies to combat AI threats, establish zero trust, and ensure data protection. Being recognized among the best in the industry is a great honor for Astellas, showcasing our commitment to innovative security thinking and the true business value it brings to the organization. Congratulations to our entire Information Security team! We look forward to celebrating our success at the CSO Conference & Awards this October. Read more about the CSO Awards: https://lnkd.in/gfH-PJUH Nick Eshkenazi Jeff Pearl #InformationSecurity #CyberSecurity #Innovation #CSOConference
-